News
Dapagliflozin reduced the total number of events, first and recurrent (337 vs 442 among the population of 17,160 patients), for an incidence rate ratio of 0.77 (95% CI, 0.64-0.92; P = .005).
Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.
Kato E, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus based on ejection fraction [published online March 18, 2019]. Circulation. Verma S, McMurray JJV.
7d
TipRanks on MSNAstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...
A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...
Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².
Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...
Dapagliflozin may exert a protective effect on kidney function in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease (ADPKD) when used in conjunction ...
Dapagliflozin was well tolerated and the rate of treatment discontinuation was low in patients with and without diabetes. Hypoglycemia and diabetic ketoacidosis developed only in patients with ...
The rate of all-cause mortality was 7.8% in the dapagliflozin arm and 8.9% in the control arm (HR, 0.87 [95% CI, 0.59-1.28]). Regarding safety, genital infections and hypotension were reported ...
5d
TipRanks on MSNAstraZeneca’s Phase I Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results